Adapta Medical, Inc. develops and patents innovative disposable urological medical devices. These products serve both inpatient and outpatient consumers. Adapta Medical has 3 issued patents, 18 pending patents, and 5 provisional patents. Several additional provisional patents are to be submitted in 2010.

Adapta Medical products address multiple needs not being met in the market today. Individuals with limited dexterity cannot use any of the intermittent catheters currently on the market. Our products will allow people with limited and even those with absent dexterity to perform self-catheterization for the first time. This includes individuals with spinal cord injury, multiple sclerosis, stroke, and many other medical conditions. Hospitals are currently using 50-year-old catheter technology that is time-consuming and leads to infections. Hospitals are now financially penalized if a urinary tract infection develops during a patient's stay.

Adapta Medical is the solution that will advance urological healthcare and revolutionize the worldwide market.

Aequorea Vision Medical is commercializing a breakthrough medical technology that will revolutionize the diagnosis and treatment of Human Papillomavirus (HPV), Bovine Papillomavirus (BPV), and potentially cervical cancer.

AVM™ SureScreen System allows physicians and veterinarians to SEE AND TREAT, meaning that they can visually identify and instantaneously treat cells damaged by HPV (the now known cause of cervical cancer) and treat animals infected by BPV before cells have the opportunity to become life threatening.

Aequorea Vision Medical is dedicated to revolutionizing cervical cancer and BPV screening tests. With AVM™ SureScreen technology we have the potential to save billions of dollars and millions of lives.

Heart Test Laboratories Inc. (HTL) is a rapidly developing medical technology company concentrating on inventing life saving devices to identify myocardial abnormalities (a restriction of blood flow to the heart), including Coronary Arterial Disease (CAD).

Heart Test Laboratories is in the final stages of releasing its new patent pending screening device, the MyoVista™, a portable, inexpensive, non invasive diagnostic test used to determine the presence and level of myocardial abnormalities and the obstruction of coronary arteries. Heart Test Laboratories MyoVista™ technology incorporates three-dimensional mapping of the heart through proprietary algorithms that continuously multiplex each of the ten surface electrodes. The MyoVista technology is derived from one to two million points in the myocardium, and since 2003, over 50,000 patients have been correlated with the MyoVista Technology to determine the presence and level of myocardial abnormalities.  A recently completed clinical trial showed an 88.9% correlation to an invasive angiogram.

Kewl Innovations is creating a new dynamic for people who use Insulin or other medication that require strict temperature management.  The small, lightweight Kewl device will control and monitor the temperature of medications over several days in various environments on a single charge.  For the first time, individuals who use temperature-controlled medications will be free from refrigerated devices, gel packs, ice chests, or other restrictions, giving them untethered freedom to live active lives.

Kewl's patent pending software ensures maximum battery life and provides an easy to understand index that accounts for product shelf life and storage temperature.  Utilizing nanotechnology, advanced software, and rechargeable batteries, the Kewl device controls and monitors medication temperature over several days in various environments.

Magaw Medical is a Fort Worth-based medical device company that has developed the new standard of care for airway management. Fifty million people worldwide have breathing tubes inserted into their airways each year. The 70-year-old device traditionally used does not provide clinicians with the best view of the vocal cords. This puts more than 3 million people each year at unnecessary risk for complications that can include brain damage and death.

Magaw has improved the traditional device with the addition of a camera and video display. We provide a cost-effective device that gives clinicians the best view of the vocal cords, significantly decreasing the risk for patients. That functionality, combined with other patent-pending features, improves ease of use, improves patient safety and diminishes the likelihood of cross contamination between patients. Founded by clinicians, for clinicians, Magaw provides a cost-effective device that establishes the new standard of care for airway management. No clinician can afford to be without Magaw.

Nanospectra Biosciences is a private company focused on the development of AuroLase® Therapy for the minimally invasive treatment of solid tumors.  Nanospectra has is raising funds to commence a clinical trial of the focal treatment of prostate cancer, a follow-on to an ongoing clinical trial for the treatment of refractory or recurrent head and neck cancers under an approved Investigational Device Exemption (IDE) in the US.  AuroLase Therapy utilizes systemically delivered particles to precisely direct the thermal destruction of solid tumors using laser energy, and is broadly applicable to other solid tumors such as brain and pancreatic cancer.  Nanospectra was founded in 2002 based on technology developed at Rice University and has licensed or owns a broad patent portfolio related to nanoparticle-based cancer treatment, imaging, and industrial applications.

Natural Dental Implants™ AG, located in Berlin, Germany, is an early-stage dental technology and services company with a disruptive, patented system for replacing non-functional teeth with anatomically shaped prostheses rather than surgical dental implants.  The REPLICATE™ Non-Surgical Tooth Replacement System enables General Dentists to replace teeth after extraction non-surgically in a single appointment, thus reducing the time, cost and inconvenience associated with current techniques.  Patients receive an aesthetically pleasing, replicate tooth (root and crown), that is functional the day it is placed.  To date the Company has received about 700,000 Euro in equity financing and is currently seeking equity financing in the amount of up to 1 million Euro to continue product development and validation and to prepare for market entry in 2011. The equity received will be leveraged by German government grants and non-dilutive, debt based fostering instruments.

NetMed Care is a branded, trademarked service, created by Advanced Medical Alliance, a Texas Corporation, that will change the way healthcare is delivered.  NetMed Care creates small on-site medical clinics, called eClinics, that offer enhanced access to quality medical care at a price 30-35% less than a traditional doctor office visit. NetMed Care uses current, cost-efficient, plug and play hardware and software components, integrated in a proprietary manner and delivered over the internet. It partners with caring, Board Certified doctors and nurses, to deliver a patient centric medical service that is customized by the patient's demographics, lifestyle, heredity and prior medical history. Plus, NetMed Care treats the patient and educates the patient which results in a positive experience and repeat visits. NetMed Care is a scalable service that can change the current doctor-care industry and deliver higher margins and higher utilization.

Ortho Kinematics, Inc. is a spine diagnostics company focused on spine motion analysis products and services. Back and neck pain is widely prevalent in the population, and is notoriously difficult to pinpoint the exact anatomic cause, using the current standard of care. This diagnostic gap can sometimes be the source of wasted health care dollars and ineffective treatments.

Our solution is the KineGraph VMA (Vertebral Motion Analyzer), an automated functional diagnostic test for the spine that uses fluoroscopy to capture the spine in motion, producing patient-specific graphs of the kinematics for each vertebral level. The KineGraph VMA replaces the outdated method of using static x-ray images of the bending spine to evaluate spine function.  Ortho Kinematics, Inc. is a company of seasoned entrepreneurs dedicated to improving the quality of spine diagnostics testing.

Palmaz Scientific has a long history of pursuing the research and development of advanced metallurgical surface nanotechnologies for the manufacture of implantable medical devices. Today by applying remarkable discoveries and advancements, Palmaz Scientific is furthering the research, development and commercialization of advanced metallurgical surface nanotechnologies for the manufacture of implantable medical devices with superior design and biocompatibility that outperform alternative treatments and products in a myriad of applications including neurology and orthopedics.

Andro Diagnostics has developed a diagnostic test for prostate cancer that requires only that a man express some semen, put it into a cup, and send it frozen to a reference lab. In a later version (now in development) the test "chips" will be built into the collection cup, the man has only to wait 5 minutes to see his result, at home. The diagnostic home test will give two results, either "Healthy," or "See a Urologist."

The total addressable market in the US is 50 Million men, and the cost of goods is quite low.

CardioMag Imaging, Inc. (CMI) is a privately held medical device company founded in 1999 and is engaged in the development and commercialization of a unique cardiac diagnostic device known as MagnetoCardioGraphs (MCG), providing Heart Health Graphics. This device integrates highly sophisticated proprietary sensors, electronics, and software. The MCG system is a non-invasive cardiac medical diagnostic device, providing unique and clinically relevant information about heart function without use of Ionizing Radiation. CardioMag's MCG system is the world's first and only MCG system to obtain FDA approval. The basis of the device relies on analyzing magnetic fields generated by the heart's electrical activity. As such, it can be applied broadly, from prevention through diagnosis, to determine the relative risk of cardiac rehabilitation. From the MCG analysis of ventricular repolarization alone, the physician can tell whether a patient has underlying coronary artery disease and-using beat-to-beat analysis-the relative risk of sudden cardiac death.

CorePLUS is an instantly scalable infrastructure platform, which is open standards based and both technology and network agnostic, providing centralized administration and provisioning of applications and services. CorePLUS delivers CoreHealth, an application delivery service that aggregates a wide variety of healthcare software to be used in medical practices, hospitals, pharmacies, laboratories and other institutions in SaaS format. On the CorePLUS cloud, hospitals can deploy, train, integrate, schedule, and update programs and IT infrastructure in a more effective way. The result is total security, total reliability and redundant data management supplied by a single vendor. No down time, no viruses, no equipment or software upgrades to worry about.  CorePLUS uses this convergent digital network to allocate activities more efficiently, and to provide a platform for companies to securely access traditional applications while harnessing these new tools which are transforming the way business is conducted. This technology frees up high-value workers to spend more time doing what they do best.

DentLight is a unique medical device company bootstrapped in 2005 and funded by Emerging Technology fund in 2008. We focus in the field of dental equipment and disposables, where we patent, design, develop, manufacture, and market dental diagnostic and treatment devices for dental clinics and hospitals. We have established two brand name products- FUSION Curing Lights and DentLight Headlights, which have been sold through all leading dental distributors. Our products have been validated as the best LED light technology by opinion leaders, independent research institutions, and dentists around the world and against the most reputable large dental manufacturers. We have won best product awards (2008 and 2010) and are winning customers with our unique products and friendly services. DentLight's technology is revolutionizing dental practice procedures for oral exams, braces, oral surgeries, restorative and cosmetics including cavity, sealant, veneers and crown/bridges with improved work efficiency and better health treatment of patients.

The ErgoNurse® is a No-Lift patient moving device for bedridden patients.  It is a solution for the multi-billion dollar problems of hospital staff injuries resulting manually lifting and moving patients and hospital acquired bed sores. The ErgoNurse allows a single giver to quickly and safely perform all the on-bed patient movements. It boosts (or pulls) patients up in bed and turns patients to avoid pressure ulcers.  It also turns them fully to their side for cleaning, dressing changes or linen changes. The ErgoNurse stands behind the bed so is out of the way when not in use.  It attaches to the existing bed linen and then by simply lowering the bed uses gravity to gently move the patient.  In our pilot studies the ErgoNurse has eliminated hospital staff injuries for three years.  The ErgoNurse is a simple, cost effective solution for eliminating most hospital staff back and shoulder injuries.

Hospitech Respiration LTD. is a start up company established in 2006 to develop medical devices for the respiratory market. Hospitech's mission is to meet the challenge of reducing complications associated with mechanical ventilation.  The company has designed and developed the AnapnoGuard™.  The AnapnoGuard™ is an innovative respiratory guard system aimed at reducing the risk of ineffective ventilation as well as preventing complications related to prolonged mechanical ventilation such as ventilator-associated pneumonia and Mechanical complications.

The system incorporates a non-invasive electronic control device as well as disposable proprietary endotracheal tubes and kits. The system has been tested successfully in pre-clinical and clinical evaluations in Israel and Europe. The entire system is CE certified and the endotracheal tube is FDA cleared (510k). Throughout 2010 and 2011 the company intends to extend the clinical studies in Europe and USA and by mid 2011 the Company intends to initiate early sales to targeted hospitals.

MedHab is developing a new medical device, StepRite®, affording medical care prescribers the ability to customize physical rehabilitation protocols to meet each patient's unique needs.   StepRite® is a wearable device that has the capability to measure body weight, pressure, gait and the flexibility of lower extremities, as well as thermal sensing. StepRite will marketed as "DME."

Medigent Health Services Inc. is an innovative healthcare service designed to provide affordable healthcare now! The basis for this service has been successfully operated in Europe since 2003. The service is simple in its concept: provide affordable, agile, high quality preventive healthcare to rural, underserved communities and those struggling to afford healthcare or who wish to have more affordable choices.

Medigent Health Centers are unique in that they are comprised of relocatable units that can be moved from location to location on an as required basis. Our focus is primarily preventive care. Prospective patients will have access to treatment facilities that provide services including:

●  Outpatient  ●  Diagnostics  ●  Ambulatory Surgery 
●  Occupational and Physical Therapy ●  Dental

Medigent, in collaboration with State Agencies, will provide Texas and other states with innovative , high quality medical delivery models, delivering affordable, high quality  healthcare.

Munogenics, Inc. is a biotech company based in Austin.  Munogenics is in collaboration with Wake Forest University with the development a new and novel treatment and prevention of cancer revolving around  a new discovery of  cancer resistancy in mice.  The cancer resistancy has now been discovered in humans as well, and can be transferred to recipient cancer patients through spontaneous regression/complete response splenocytes, bone marrow cells or enriched marophages, either for prevention against subsequent cancer challenges or eradication of established malignancy at distant sites.

An assay has been developed to test for cancer killing activity in humans.  This test can be used to identify potential cancer resistant donors.

Munogenics is presently going into Phase II clinical trials utilizing this concept on various types of solid tumors in cancer patients.

Otosound Products, LLC ("Otosound") is a market-ready, private UCSD tech transfer company uniquely poised to become the market leader in treating Tinnitus, a condition characterized by ringing in the ears caused by pathologies of the central nervous system. 

We are the first and only FDA cleared sound diagnostic and therapeutic addressing the root cause of the pathology.  Today, medical treatment addresses only the symptoms based upon a subjective patient questionnaire.  We represent an audiology paradigm shift addressing web portal diagnostic delivery and insurance reimbursement status.

100 million people suffer from Tinnitus and because of our loud industrial world, war and personal iPod type devices; the condition is worsening and artificially accelerating among younger populations. Tinnitus is a consistent top 10 patient complaint and represents an $8.6B addressable market for Otosound. We have a seasoned management team with accomplished start-ups, funding and successful venture capital exits.

2010 Venture Capital Panel Speakers

2010 Angel Panel Speakers

2010 North Texas RCIC/ETF Update

2010 Venture Capital Update